This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
-
Pinnacle Research Group, Anniston, Alabama, United States, 36207-4781
AllerVie Clinical Research, Birmingham, Alabama, United States, 35209-6802
Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States, 35211-1320
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS, Dothan, Alabama, United States, 36305
Pulmonary Associates of Mobile PC, Mobile, Alabama, United States, 36608-3135
Pulmonary Associates, Glendale, Arizona, United States, 85306-4669
Synexus Clinical Research US, Inc. - Phoenix West, Glendale, Arizona, United States, 85306-4678
AES - DRS - Synexus Clinical Research US, Inc. - Tucson, Tucson, Arizona, United States, 85741-3118
Lynn Institute of The Ozarks - ERN - PPDS, Little Rock, Arkansas, United States, 72204-1505
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
40 Years to 80 Years
ALL
No
Hoffmann-La Roche,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2025-06-01